Invest in Theralase®
Theralase® is a clinical stage pharmaceutical company focused on the research and clinical development of light-activated Photo Dynamic Compounds (“PDCs”) with a primary focus of destroying cancer safely and effectively (e.g.: lung, breast, brain, bladder), bacteria, and viruses.
Theralase ®’s pipeline consists of:
Pivotal Phase II clinical study for patients with Non-Muscle Invasive Bladder Cancer (“NMIBC”), which if successful, could lead to the commercialization of it’s lead PDC – TLD-1433 by the end of 2025. The NMIBC market opportunity is estimated to be approximately $1.1 to $5 billion annually.
Preclinical development for Non- Small Cell Lung Cancer (“NSCLC”) and Glio Blastoma Multiforme (“GBM”) utilizing an injectable form of Rutherrin (TLD-1433 + Transferrin)
Preclinical research of TLD-1433 as a virus vaccine candidate that has been demonstrated as a fast and effective anti-viral inactivation of viruses including COVID-19, in-vitro.
Theralase®’s PDCs are patent protected in Canada, USA and Internationally (42 issued patents).
Our Partners
As part of our continuing mission to design, develop, and manufacture cutting-edge laser technologies, Theralase® has partnered with individuals and groups at the following institutions and organizations.
